Ambrilia Biopharma Inc. Completes Patient Recruitment for the Phase 3 Pivotal Clinical Trial of its Prolonged Release Formulation of Octreotide

MONTREAL, QUEBEC--(MARKET WIRE)--Aug 28, 2007 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News) announced today that it has completed patient recruitment into the pivotal phase 3 clinical trial of its proprietary prolonged release formulation of Octreotide (“C2L”).